Affinity Asset Advisors »

Passage Bio shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Passage Bio (PASG) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Passage Bio

Tip: Access up to 7 years of quarterly data

All positions including Passage Bio held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Passage Bio by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2024-03-31 $357k 264k 1.35

More positions owned by Affinity Asset Advisors

Spdr Ser Tr S&p Biotech Put Option (XBI)
Teva Pharmaceutical Inds Sponsored Ads Call Option (TEVA)
Moderna Put Option (MRNA)
Apogee Therapeutics (APGE)
Xenon Pharmaceuticals (XENE)
Madrigal Pharmaceuticals (MDGL)
Crinetics Pharmaceuticals In (CRNX)
Autolus Therapeutics Spon Ads (AUTL)
Celldex Therapeutics Com New (CLDX)
Arcellx Common Stock (ACLX)
Vera Therapeutics Cl A (VERA)
Inozyme Pharma (INZY)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Kura Oncology (KURA)
Spyre Therapeutics Com New (SYRE)

View all positions for Affinity Asset Advisors

Top funds holding Passage Bio

OrbiMed Advisors
Versant Venture Management
Lynx1 Capital Management
New Leaf Venture Partners
Vanguard Group
Tang Capital Management
Renaissance Technologies
Acadian Asset Management
BlackRock
Millennium Management
Bridgeway Capital Management
Acuitas Investments
Geode Capital Management
Affinity Asset Advisors
Citadel Advisors

View all funds holding Passage Bio